The DOI matches its Crossref record.
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results
Open accessAbstract
AIM: The MITOCARE study evaluated the efficacy and safety of TRO40303 for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI). METHODS: Patients presenting with STEMI within 6 h of the onset of pain randomly received TRO40303 (n = 83) or placebo (n = 80) via i.v. bolus injection prior to balloon inflation during primary percutaneous coronary intervention in a double-blind manner. The primary endpoint was infarct size expressed as area under the curve (AUC) for creatine kinase (CK) and for troponin I (TnI) over 3 days. Secondary endpoints included measures of infarct size using cardiac magnetic resonance (CMR) and safety outcomes. RESULTS: The median pain-to-balloon time was 180 min for both groups, and the median (mean) door-to-balloon time was 60 (38) min for all sites. Infarct size, as measured by CK and TnI AUCs at 3 days, was not significantly different between treatment groups. There were no significant differences in the CMR-assessed myocardial salvage index (1-infarct size/myocardium at risk) (mean 52 vs. 58% with placebo, P = 0.1000), mean CMR-assessed infarct size (21.9 g vs. 20.0 g, or 17 vs. 15% of LV-mass) or left ventricular ejection fraction (LVEF) (46 vs. 48%), or in the mean 30-day echocardiographic LVEF (51.5 vs. 52.2%) between TRO40303 and placebo. A greater number of adjudicated safety events occurred in the TRO40303 group for unexplained reasons. CONCLUSION: This study in STEMI patients treated with contemporary mechanical revascularization principles did not show any effect of TRO40303 in limiting reperfusion injury of the ischaemic myocardium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Evolving Therapies for Myocardial Ischemia/Reperfusion Injury
Ibáñez, B., Heusch, G., Ovize, M., & Van de Werf, F. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.032 · Cited by 1,009
New insights into acute pancreatitis
Lee, P. J., & Papachristou, G. I. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0158-2 · Cited by 904
Mitochondria as a therapeutic target for common pathologies
Murphy, M. P., & Hartley, R. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.174 · Cited by 827
Heusch, G. (2015) · Circulation Research · doi:10.1161/circresaha.116.305348 · Cited by 811
Heusch, G., & Gersh, B. J. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw224 · Cited by 676
Metadata
- Authors
- Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.-L., Carlsson, M., Clemmensen, P., Cuvier, V., Danchin, N., Dubois-Rande, J.-L., Engblom, H., Erlinge, D., Firat, H., Halvorsen, S., Hansen, H. S., Hauke, W., Heiberg, E., Koul, S., Larsen, A.-I., Le Corvoisier, P., Nordrehaug, J. E., Paganelli, F., Pruss, R. M., Rousseau, H., Schaller, S., Sonou, G., Tuseth, V., Veys, J., Vicaut, E., & Jensen, S. E.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-09-01
- Volume
- 36
- Issue
- 2
- Pages
- 112-119
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2143830716
- Cited by
- 193
- References
- 0
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. https://app.cochat.ai/papers/10.1093/eurheartj/ehu331
- The paper
- Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.-L., Carlsson, M., Clemmensen, P., Cuvier, V., Danchin, N., Dubois-Rande, J.-L., Engblom, H., Erlinge, D., Firat, H., Halvorsen, S., Hansen, H. S., Hauke, W., Heiberg, E., Koul, S., Larsen, A.-I., Le Corvoisier, P., . . . Jensen, S. E. (2015). Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.